scholarly journals Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group

2013 ◽  
Vol 8 (1) ◽  
pp. 47 ◽  
Author(s):  
Thai Tran ◽  
David Mitchell ◽  
David Dix ◽  
Sonia Cellot ◽  
Marie-Chantal Ethier ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Research Group ◽  
Myeloid Leukemia ◽  
Children With Down Syndrome ◽  
Acute Myeloid

scholarly journals Two Novel GATA1 Mutations in Transient Abnormal Myelopoiesis of Thai Neonates with Down Syndrome

2019 ◽  
Vol 08 (04) ◽  
pp. 187-192
Author(s):  
Kanokporn Chukua ◽  
Chayanont Netsawang ◽  
Kittipoom Padungthai ◽  
Thanitchet Khetkham ◽  
Piyaporn Chokevittaya ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Risk Factor ◽  
Myeloid Leukemia ◽  
Heterozygous Mutation ◽  
Frameshift Mutations ◽  
Children With Down Syndrome ◽  
Transient Abnormal Myelopoiesis ◽  
Nucleotide Insertion ◽  
Acute Myeloid

AbstractChildren with Down syndrome (DS) are 150 times more likely to develop acute myeloid leukemia (ML-DS), compared with those without. One risk factor is transient abnormal myelopoiesis (TAM). Somatic truncating GATA1 mutations are found in most TAM patients and are markers for future ML-DS. We identified two novel frameshift mutations in our seven newborns with DS and TAM: a heterozygous mutation of 17 nucleotide duplication (c.154_170 dup) and a heterozygous 9-nucleotide deletion combined with a 2-nucleotide insertion (c.150_158delins CT). Both mutations introduced a truncated GATA1 protein. Thus, neonates with DS and TAM require frequent ML-DS monitoring.

scholarly journals Down syndrome and AML: where do we go from here?

Blood ◽  
2017 ◽  
Vol 129 (25) ◽  
pp. 3274-3275 ◽  
Author(s):  
Daisuke Tomizawa ◽  
E. Anders Kolb
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Young Children ◽  
Myeloid Leukemia ◽  
Intensive Therapy ◽  
Therapeutic Options ◽  
Intensive Chemotherapy ◽  
Children With Down Syndrome ◽  
Nonrandomized Trial ◽  
Acute Myeloid

It is well documented that young children with Down syndrome (DS) have both a 500-fold increased incidence of acute myeloid leukemia (ML-DS) and a decreased tolerance of intensive chemotherapy. In this issue of Blood, Uffmann et al present the results of a large, multicentered, international, nonrandomized trial reducing the etoposide exposure while preserving the excellent outcomes reported in previous trials.1 This trial builds on international experience demonstrating that most young children with ML-DS may be cured with less intensive therapy, and confirms that there remains a significant subset of patients for whom we have limited therapeutic options.

scholarly journals Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421

2008 ◽  
Vol 26 (3) ◽  
pp. 414-420 ◽  
Author(s):  
Maureen M. O'Brien ◽  
Jeffrey W. Taub ◽  
Myron N. Chang ◽  
Gita V. Massey ◽  
Kimo C. Stine ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Disease Free Survival ◽  
Remission Induction ◽  
Oncology Group ◽  
Free Survival ◽  
Children With Down Syndrome ◽  
Age Related ◽  
Acute Myeloid

Purpose To determine the outcomes, with particular attention to toxicity, of children with Down syndrome (DS) and acute myeloid leukemia (AML) treated on Pediatric Oncology Group (POG) protocol 9421. Patients and Methods Children with DS and newly diagnosed AML (n = 57) were prospectively enrolled onto the standard-therapy arm of POG 9421 and were administered five cycles of chemotherapy, which included daunorubicin 135 mg/m2 and mitoxantrone 80 mg/m2. Outcomes and toxicity were evaluated prospectively and were compared with the non-DS–AML cohort (n = 565). A retrospective chart review was performed to identify adverse cardiac events. Results In the DS-AML group, 54 patients (94.7%) entered remission. One experienced induction failure and two died. Of the 54 who entered remission, three relapsed and six died as a result of other causes. The remission induction rate was similar in the non-DS–French-American-British (FAB) M7 (91.7%) and non-DS–non-M7 (89.3%) groups. The 5-year overall survival was significantly better in the DS-AML group (78.6%) than in the non-DS–M7 (36.3%) or the non-DS–non-M7 (51.8%) groups (P < .001). No age-related difference in 5-year, event-free survival was seen between patients younger than 2 years (75.8%) and those aged 2 to 4 years (78.3%). Symptomatic cardiomyopathy developed in 10 patients (17.5%) with DS-AML during or soon after completion of treatment; three died as a result of congestive heart failure. Conclusion The POG 9421 treatment regimen was highly effective in both remission induction and disease-free survival for patients with DS-AML. However, there was a high incidence of cardiomyopathy, which supports current strategies for dose reduction of anthracyclines in this patient population.

scholarly journals Treating acute myeloid leukemia among children with down syndrome

2020 ◽  
Vol 41 (6) ◽  
pp. 841
Author(s):  
AK Simalti ◽  
Rajan Kapoor ◽  
KarthikRam Mohan ◽  
Shuvendu Roy ◽  
SumanKumar Pramanik ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Children With Down Syndrome ◽  
Acute Myeloid

Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Cancer Group Study 2891

2003 ◽  
Vol 21 (18) ◽  
pp. 3415-3422 ◽  
Author(s):  
Alan S. Gamis ◽  
William G. Woods ◽  
Todd A. Alonzo ◽  
Allen Buxton ◽  
Beverly Lange ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Age At Diagnosis ◽  
High Dose ◽  
Children With Down Syndrome ◽  
Cancer Group ◽  
Negative Effect ◽  
Grade 3 ◽  
Acute Myeloid

Purpose: To determine the outcome of children with Down syndrome (DS) and acute myeloid leukemia (AML) receiving standard timing chemotherapy without bone marrow transplantation (BMT), with determination of prognostic factors. Patients and Methods: Children with DS and newly diagnosed AML or myelodysplasia were prospectively enrolled on Children’s Cancer Group study 2891 (N = 161) and treated uniformly with four standard timing induction courses of dexamethasone, cytarabine arabinoside, 6-thioguanine, etoposide, daunorubicin (DCTER) followed by intensively timed high-dose cytarabine. Results: Children with DS were significantly younger at diagnosis than those without (median age, 1.8 v 7.5 years, respectively; P < .001), with more megakaryocytic leukemia (70% v 6%; P < .001). Higher complete remission rates (91%) were achieved in children with DS than among those without DS (75%; P < .001). Equivalent grade 3 to 4 toxicity (29% v 30%; P = .84) was seen, though children with DS had greater pulmonary toxicity (P < .01) during induction and mucositis during intensification (P = .12). Children with DS had significantly better 8-year event-free survival (EFS; 77% v 21% standard and 40% intensive induction; P < .0001). Multivariate analysis in children with DS revealed that only age at diagnosis of 2 years or older was a risk factor for greater relapse risk (odds ratio, 4.9; P = .006) and worse survival. Children between ages 0 to 2 years (n = 94) had a 6-year EFS of 86%; those from 2 to 4 years (n = 58), 70%; and those older than 4 years (n = 9), 28%. Remission failures were the primary reason for worse 6-year EFSs (1% in those 0 to 2 years v 14% if >2 years; P = .002). Conclusion: Outcome for children with DS and AML is excellent with standard induction therapy, but declines with increasing age.

MTHFR677C→T And 1298A→C POLYMORPHISMS IN CHILDREN WITH DOWN SYNDROME AND ACUTE MYELOID LEUKEMIA IN BRAZIL

2008 ◽  
Vol 25 (8) ◽  
pp. 744-750 ◽  
Author(s):  
Márcia R. Amorim ◽  
Crisiane Wais Zanrosso ◽  
Isis Q. Magalhães ◽  
Simone C. Pereira ◽  
Alexandre Figueiredo ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Children With Down Syndrome ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document